Medrx Co

Medrx Co Rule of 40

The Rule of 40 of Medrx Co (4586.T) as of Oct 17, 2026 is -785.79 %. In the previous year, Rule of 40 was 462.90 % — a change of -269.75% (lower).

Rule of 40

-785.79 %

YoY

-269.75%

Last updated:

Rule of 40 of Medrx Co is 2025 -785.79 % . Rule of 40 of Medrx Co was 2024 462.90 % . It decreases by -269.75% lower compared to the previous year.

The Medrx Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-15,260.35 JPY
Jan 1, 2019
964.44 JPY
Jan 1, 2020
-1,014.43 JPY
Jan 1, 2021
-12,802.03 JPY
Jan 1, 2022
-1,249.46 JPY
Jan 1, 2023
-3,211.34 JPY
Jan 1, 2024
462.90 JPY
Jan 1, 2025
-785.79 JPY
The Medrx Co Rule of 40 history
YEARRule of 40YoY
-785.79 %-269.75%
462.90 %-114.41%
-3,211.34 %+157.02%
-1,249.46 %-90.24%
-12,802.03 %+1,161.99%
-1,014.43 %-205.18%
964.44 %-106.32%
-15,260.35 %-5,674.25%
273.77 %-104.52%
-6,051.02 %+131.35%
-2,615.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co Ltd is a pharmaceutical company based in Higashikagawa-shi, Japan, operating within the Health Care sector. The company has 22 employees and went public on February 13, 2013, with its ticker listed as 4586.T on the Tokyo Stock Exchange. Medrx focuses on pharmaceutical drug development utilizing transdermal absorption technology. The company's website is www.medrx.co.jp. Medrx develops new medicines using percutaneous absorption formulation technology, specifically employing ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). These technologies leverage ionic liquid characteristics and nano colloidization to enhance drug efficacy, minimize side effects, and provide alternative administration methods for patients who cannot take medications orally. The company aims to create medicines with innovative value by addressing challenges such as patient compliance and delivery methods for difficult-to-administer drugs. Medrx is headquartered in Higashikagawa-shi, Kagawa Prefecture, and maintains a small operational scale with a dedicated team of 22 full-time employees. The company's business model centers on developing pharmaceuticals that improve patient outcomes through advanced transdermal delivery systems, targeting specific medical needs where traditional oral administration is impractical or ineffective. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Rule of 40 of Medrx Co is -785.79 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Medrx Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Medrx Co

All Key Metrics — Medrx Co